- Home
- ADXN vs OGEN Comparison
ADXN vs OGEN Comparison
Compare ADXN & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- OGEN
- Stock Information
- Founded
- ADXN 2002
- OGEN 1996
- Country
- ADXN Switzerland
- OGEN United States
- Employees
- ADXN N/A
- OGEN N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ADXN Health Care
- OGEN Health Care
- Exchange
- ADXN Nasdaq
- OGEN Nasdaq
- Market Cap
- ADXN 8.5M
- OGEN 5.4M
- IPO Year
- ADXN N/A
- OGEN N/A
- Fundamental
- Price
- ADXN $9.46
- OGEN $1.30
- Analyst Decision
- ADXN
- OGEN
- Analyst Count
- ADXN 0
- OGEN 0
- Target Price
- ADXN N/A
- OGEN N/A
- AVG Volume (30 Days)
- ADXN 24.2K
- OGEN 213.2K
- Earning Date
- ADXN 11-21-2025
- OGEN 11-12-2025
- Dividend Yield
- ADXN N/A
- OGEN N/A
- EPS Growth
- ADXN N/A
- OGEN N/A
- EPS
- ADXN N/A
- OGEN N/A
- Revenue
- ADXN $210,347.00
- OGEN N/A
- Revenue This Year
- ADXN $86.57
- OGEN N/A
- Revenue Next Year
- ADXN N/A
- OGEN N/A
- P/E Ratio
- ADXN N/A
- OGEN N/A
- Revenue Growth
- ADXN N/A
- OGEN N/A
- 52 Week Low
- ADXN $6.51
- OGEN $1.01
- 52 Week High
- ADXN $12.05
- OGEN $18.90
- Technical
- Relative Strength Index (RSI)
- ADXN 51.88
- OGEN 48.72
- Support Level
- ADXN $9.01
- OGEN $1.29
- Resistance Level
- ADXN $9.98
- OGEN $1.34
- Average True Range (ATR)
- ADXN 0.79
- OGEN 0.07
- MACD
- ADXN 0.03
- OGEN -0.01
- Stochastic Oscillator
- ADXN 27.25
- OGEN 22.50
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.